Nama's AI scorecard currently rates Repligen Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is RGEN's P/E ratio?

Repligen trades at a trailing price-to-earnings ratio of 85.0.

When does RGEN report earnings?

Repligen's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.52.

What is the RGEN price target?

The median analyst price target from 20 analysts is $202.00, with a range of $175.00 – $235.00.

Is RGEN Shariah compliant?

Nama's AAOIFI-style screen reads Repligen as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Repligen (RGEN)

Healthcare · Medical Instruments Supplies · NASDAQ

Repligen (RGEN) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $11.09B, a trailing price-to-earnings ratio of 85.0 and a free-cash-flow yield of 0.9%. Over the most recent reported fiscal year, revenue grew 16.4% and free cash flow per share fell 36.4%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 6.8/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +15.3% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-42.2%

How far the last close sits under the highest price of the past five years.

Market cap	$11.09B
Trailing P/E	85.0
Price / book	4.6
Price / sales	13.8
FCF yield	0.9%
Dividend yield	—
Gross margin	53.8%
Operating margin	8.3%
Net margin	5.3%
Revenue growth (YoY)	+16.4%
Revenue growth (3-yr annual)	-2.7%
EPS growth (YoY)	+15.5%
FCF/share growth (YoY)	-36.4%
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

RGEN earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $0.52). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$0.53	$0.46	+15.2%	$209.31M
Q2 2026	Jul 28, 2026	$0.54	$0.45	+20.0%	$204.13M
Q1 2026	May 5, 2026	$0.48	$0.39	+23.1%	$194.25M
Q4 2025	Feb 24, 2026	$0.49	$0.44	+11.4%	$197.91M

RGEN analyst price target

Median target $202.00 from 20 analysts, ranging $175.00 – $235.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live RGEN data on Nama Insights →

Recent Congressional trades

Repligen trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Jefferson Shreve	House	Sell	$15,001 - $50,000	May 8, 2025

RGEN FAQ

Is RGEN a buy?: Nama's AI scorecard currently rates Repligen Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is RGEN's P/E ratio?: Repligen trades at a trailing price-to-earnings ratio of 85.0.
When does RGEN report earnings?: Repligen's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.52.
What is the RGEN price target?: The median analyst price target from 20 analysts is $202.00, with a range of $175.00 – $235.00.
Is RGEN Shariah compliant?: Nama's AAOIFI-style screen reads Repligen as Can't Tell. A figure the screen needs is missing, so it can't tell.